Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi center, randomized, placebo controlled parallel group study to
evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to
severely active ulcerative colitis